Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-648414 + midazolam
- Development stage
- Unknown
- Lead developer
- Shionogi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
S-648414 + midazolam is a drug combination used in clinical pharmacology studies to evaluate the drug-drug interaction (DDI) profile of S-648414, an investigational antiviral agent. S-648414 is a small molecule 3C-like (3CL) protease inhibitor developed by Shionogi for the treatment of COVID-19 (SARS-CoV-2 infection). Midazolam, a short-acting benzodiazepine and positive allosteric modulator of the GABA-A receptor, is co-administered as a sensitive probe substrate for the cytochrome P450 3A4 (CYP3A4) enzyme. These studies are designed to determine whether S-648414 inhibits or induces CYP3A4, which helps characterize its potential to interact with other medications metabolized by this pathway, a critical step in the clinical development of antiviral therapies.
- Brand names
- SSP-004184SS + midazolam
- Other names
- midazolamS-648414 and midazolamS648414 and midazolamS 648414 and midazolam
02
Targets
CYP3A4 (Cytochrome P450 3A4)
Beyond the preview
Go deeper on S-648414 + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-648414 + midazolam.